lactic acid has been researched along with Delayed Graft Function in 4 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Delayed Graft Function: General dysfunction of an organ occurring immediately following its transplantation. The term most frequently refers to renal dysfunction following KIDNEY TRANSPLANTATION.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kostidis, S | 1 |
| Bank, JR | 1 |
| Soonawala, D | 1 |
| Nevedomskaya, E | 1 |
| van Kooten, C | 1 |
| Mayboroda, OA | 1 |
| de Fijter, JW | 1 |
| Kaths, JM | 1 |
| Echeverri, J | 1 |
| Chun, YM | 1 |
| Cen, JY | 1 |
| Goldaracena, N | 1 |
| Linares, I | 1 |
| Dingwell, LS | 1 |
| Yip, PM | 1 |
| John, R | 1 |
| Bagli, D | 1 |
| Mucsi, I | 1 |
| Ghanekar, A | 1 |
| Grant, DR | 1 |
| Robinson, LA | 1 |
| Selzner, M | 1 |
| Robert, R | 1 |
| Guilhot, J | 1 |
| Pinsard, M | 1 |
| Longeard, PL | 1 |
| Jacob, JP | 1 |
| Gissot, V | 1 |
| Hauet, T | 1 |
| Seguin, F | 1 |
| Bhangoo, RS | 1 |
| Hall, IE | 1 |
| Reese, PP | 1 |
| Parikh, CR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Angiotensin II in the Perioperative Management of Hypotension in Kidney Transplant[NCT04529005] | Phase 4 | 20 participants (Actual) | Interventional | 2020-08-13 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Duration of vasopressor usage while in the operating room measured in hours of usage presented as median and IQR. (NCT04529005)
Timeframe: Duration of usage during the transplant surgery - presented in hours
| Intervention | hours (Median) |
|---|---|
| Angiotensin II (Giapreza) | 1 |
The presence of arrhythmia was confirmed via EKG, flowsheet, or note documentation from the electronic medical record. (NCT04529005)
Timeframe: From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Angiotensin II (Giapreza) | 1 |
The presence of Delayed Graft Function was captured for each patient and defined by the need for renal replacement therapy up to 7 days post-operative. (NCT04529005)
Timeframe: From post-op to 7 days post-op
| Intervention | Participants (Count of Participants) |
|---|---|
| Angiotensin II (Giapreza) | 2 |
The presence of post-operative fungal infections were captured prior to discharge as documented by the clinical care team in the electronic medical record. (NCT04529005)
Timeframe: From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Angiotensin II (Giapreza) | 0 |
The presence of hyperglycemia was captured for each patient and was determined by those patients requiring the use of an insulin infusion after their transplant surgery. (NCT04529005)
Timeframe: From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Angiotensin II (Giapreza) | 1 |
The presence of digital or other peripheral/visceral ischemia was captured from reviewing chart documentation for each patient. (NCT04529005)
Timeframe: From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Angiotensin II (Giapreza) | 0 |
Incidence of venous or arterial thrombosis occurring during the hospitalization for kidney transplant (captured by ultrasound or other diagnostic imaging) (NCT04529005)
Timeframe: From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Angiotensin II (Giapreza) | 0 |
1 review available for lactic acid and Delayed Graft Function
| Article | Year |
|---|---|
Deceased-donor kidney perfusate and urine biomarkers for kidney allograft outcomes: a systematic review.
Topics: Acute-Phase Proteins; Biomarkers; Cadaver; Delayed Graft Function; Glutathione Transferase; Humans; | 2012 |
1 trial available for lactic acid and Delayed Graft Function
| Article | Year |
|---|---|
Urinary metabolites predict prolonged duration of delayed graft function in DCD kidney transplant recipients.
Topics: Adult; Aged; Amino Acids, Branched-Chain; Area Under Curve; Biomarkers; Delayed Graft Function; Fema | 2019 |
2 other studies available for lactic acid and Delayed Graft Function
| Article | Year |
|---|---|
Continuous Normothermic Ex Vivo Kidney Perfusion Improves Graft Function in Donation After Circulatory Death Pig Kidney Transplantation.
Topics: Animals; Aspartate Aminotransferases; Biomarkers; Cold Ischemia; Creatinine; Delayed Graft Function; | 2017 |
A pair analysis of the delayed graft function in kidney recipient: the critical role of the donor.
Topics: Adolescent; Adult; Age Factors; Aged; Biomarkers; Brain Death; Child; Citric Acid; Delayed Graft Fun | 2010 |